---
title: "Cobenfy (xanomeline and trospium chloride) in schizophrenia: Pharmacology questions"
description: "Pharmacology questions on Cobenfy (xanomeline and trospium chloride) in schizophrenia, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does COBENFY work (mechanism of action)? How is COBENFY metabolized? What is the half-life of COBENFY? What are the inactive ingredients in COBENFY? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/cobenfy--schizophrenia/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Cobenfy (xanomeline and trospium chloride) in schizophrenia: Pharmacology questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Cobenfy](https://packageinserts.bms.com/pi/pi_cobenfy.pdf)

## Mechanism

<a id="cobenfy-muscarinic-components"></a>

### How does COBENFY work (mechanism of action)?

> “COBENFY is a combination of xanomeline (M1/M4 muscarinic agonist) and trospium chloride (muscarinic antagonist).<sup>1,2,5</sup>
>
> Xanomeline
>
> Selective* activation of M1 and M4 delivers the effect in the CNS<sup>1,6</sup>
>
> Trospium chloride
>
> Antagonizes the muscarinic receptors primarily in the peripheral tissues<sup>1</sup>
>
> The mechanism of action of COBENFY in the treatment of schizophrenia is unclear<sup>1</sup>”

Source: [COBENFY: COBENFY™ (xanomeline and trospium chloride) Mechanism of Action | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/moa#:~:text=COBENFY%20is%20a%20combination%20of,the%20treatment%20of%20schizophrenia%20is)

> “COBENFY does not bind to dopamine D2 receptors<sup>1,2,5</sup>”

Source: [COBENFY: COBENFY™ (xanomeline and trospium chloride) Mechanism of Action | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/moa#:~:text=COBENFY%20does%20not%20bind%20to%20dopamine%20D2)

> “*	Xanomeline binds to muscarinic receptors M1 to M5 with comparable affinity and exhibits higher agonist activity at the M1 and M4 receptors.<sup>1</sup>”

Source: [COBENFY: COBENFY™ (xanomeline and trospium chloride) Mechanism of Action | For HCPs, captured 2026-11-08](https://www.cobenfyhcp.com/moa#:~:text=Xanomeline%20binds%20to%20muscarinic%20receptors,at%20the%20M1%20and%20M4)

## Pharmacokinetics

<a id="cobenfy-metabolism"></a>

### How is COBENFY metabolized?

> “Table 3:	
> Pharmacokinetic Properties of COBENFY
> Parameter
> Xanomeline
> Trospium
> Distribution
> 	 	 Central volume of 
> distribution (oral)
> 10,800 Liters 
> 531 Liters
> 	 	 Plasma protein binding 
> Approximately 95%
> Approximately 80%
> Elimination
> 	 	 Half-life (t1/2)
> 5 hours 
> 6 hours
> 	 	 Apparent clearance 
> 1950 Liters/hour
> 796 Liters/hour
> 	 	 Renal clearance 
> 0.085 Liters/hour
> 21 Liters/hour
> 	 Metabolism
> 	 	 Primary 
> metabolic 
> pathways 
> CYP450
> 2D6, 2B6, 1A2, 2C9, and 2C19
> Unlikely
> Other
> Flavin monooxygenases (FMO1 
> and FMO3)
> Ester hydrolysis and glucuronic 
> acid conjugation
> (not fully characterized)”

Source: [COBENFY: Prescribing information, page 6, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_cobenfy.pdf#page=6)

<a id="cobenfy-half-life"></a>

### What is the half-life of COBENFY?

> “Table 3:	
> Pharmacokinetic Properties of COBENFY
> Parameter
> Xanomeline
> Trospium
> Distribution
> 	 	 Central volume of 
> distribution (oral)
> 10,800 Liters 
> 531 Liters
> 	 	 Plasma protein binding 
> Approximately 95%
> Approximately 80%
> Elimination
> 	 	 Half-life (t1/2)
> 5 hours 
> 6 hours”

Source: [COBENFY: Prescribing information, page 6, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_cobenfy.pdf#page=6)

## Components

<a id="cobenfy-inactive-ingredients"></a>

### What are the inactive ingredients in COBENFY?

> “Inactive ingredients: The xanomeline tartrate pellets contain ascorbic acid, microcrystalline 
> cellulose, and talc.
> The trospium chloride pellets contain lactose monohydrate, microcrystalline cellulose, and talc.
> The capsules, printed with black ink, contain black iron oxide (only 100 mg/20 mg), 
> hypromellose, red iron oxide, titanium dioxide, and yellow iron oxide (only 50 mg/20 mg and 
> 100 mg/20 mg).”

Source: [COBENFY: Prescribing information, page 5, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_cobenfy.pdf#page=5)

## Related pages
- [Medical information: Cobenfy (xanomeline and trospium chloride): Schizophrenia](https://www.evicenter.com/medical-information/cobenfy--schizophrenia)
- [Indication](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/safety)
- [Specific populations](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/cobenfy--schizophrenia/access-and-coverage)
